vitamin C in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Zhang, 2020 0.50 [0.17; 1.50]
0.50 [0.17 ; 1.50 ] Zhang, 2020 1 0% 56 NA not evaluable deathsdetailed results Cao, 2020 (REV) 6.50 [0.30; 138.87]
Zhang, 2020 0.50 [0.17; 1.50]
1.19 [0.11 ; 12.85 ] Cao, 2020 (REV), Zhang, 2020 2 58% 97 moderate not evaluable deaths (time to event analysis only)detailed results Zhang, 2020 0.50 [0.17; 1.50]
0.50 [0.17 ; 1.50 ] Zhang, 2020 1 0% 56 NA not evaluable clinical deteriorationdetailed results Cao, 2020 (REV) 9.18 [0.45; 186.37]
Zhang, 2020 0.87 [0.23; 3.27]
1.89 [0.22 ; 16.48 ] Cao, 2020 (REV), Zhang, 2020 2 49% 97 moderate not evaluable clinical improvementdetailed results Cao, 2020 (REV) 0.60 [0.30; 1.20]
0.60 [0.30 ; 1.20 ] Cao, 2020 (REV) 1 0% 42 NA not evaluable clinical improvement (14-day)detailed results Cao, 2020 (REV) 0.50 [0.14; 1.73]
0.50 [0.14 ; 1.73 ] Cao, 2020 (REV) 1 0% 41 NA not evaluable clinical improvement (21-day)detailed results Cao, 2020 (REV) 0.67 [0.10; 4.48]
0.67 [0.10 ; 4.48 ] Cao, 2020 (REV) 1 0% 41 NA not evaluable clinical improvement (7-day)detailed results Cao, 2020 (REV) 0.42 [0.07; 2.61]
0.42 [0.07 ; 2.61 ] Cao, 2020 (REV) 1 0% 41 NA not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 (REV) 0.60 [0.30; 1.20]
0.60 [0.30 ; 1.20 ] Cao, 2020 (REV) 1 0% 42 NA not evaluable radiologic improvement (14-day)detailed results Cao, 2020 (REV) 0.18 [0.03; 0.99]
0.18 [0.03 ; 0.99 ] Cao, 2020 (REV) 1 0% 41 NA not evaluable serious adverse eventsdetailed results Cao, 2020 (REV) 9.18 [0.45; 186.37]
9.18 [0.45 ; 186.37 ] Cao, 2020 (REV) 1 0% 41 NA not evaluable adverse eventsdetailed results Cao, 2020 (REV) 0.63 [0.15; 2.66]
0.63 [0.15 ; 2.66 ] Cao, 2020 (REV) 1 0% 41 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-28 23:39 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 523,885
- roots T: 290